Priority Area Moorfields Pharmaceuticals: Implement the agreed restructuring of our pharmaceuticals commercial activities to deliver a commercially viable business. Executive Lead Alan Krol Summary of Progress for Quarter 3 RAG Summary of Progress for Quarter 4 RAG Some objectives achieved but financial objectives below plan Review of strategic options underway through the process established and plans for Ireland under revision. by the Trust and good progress being made. Financial objectives for the products business below plan due to exceptional costs associated with restructuring the business. Consolidated business (including manufacturing) on budget. Priority Area Detailed Q3 Objective Q3 Progress RAG Detailed Q4 Q4 Progress RAG Objective Following closure of the Review and update marketing Marketing plans updates with Develop strategic Strategic options have plans in relation to CCGs Key Account Managers options for the long been identified and Moorfields process established by
Priority Area Moorfields Pharmaceuticals: Implement the agreed restructuring of our pharmaceuticals commercial activities to deliver a commercially viable business. Executive Lead Alan Krol Summary of Progress for Quarter 3 RAG Summary of Progress for Quarter 4 RAG Some objectives achieved but financial objectives below plan and plans for Ireland under revision. Review of strategic options underway through the process established by the Trust and good progress being made. Financial objectives for the products business below plan due to exceptional costs associated with restructuring the business. Consolidated business (including manufacturing) on budget. Priority Area Detailed Q3 Objective Q3 Progress RAG Detailed Q4 Objective Q4 Progress RAG Following closure of the Moorfields Review and update marketing plans in relation to CCGs Marketing plans updates with Key Account Managers Develop strategic options for the long Strategic options have been identified and process established by